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Abstract 
The aim of this paper is to assess the clinical
efficacy of non-invasive ventilation (NIV) in
avoiding endotracheal intubation (ETI), to
demonstrate clinical and gasometric improve-
ment and to identify predictive risk factors asso-
ciated with NIV failure. An observational
prospective clinical study was carried out.
Included Patients with acute respiratory disease
(ARD) treated with NIV, from November 2006 to
January 2010 in a Pediatric Intensive Care Unit
(PICU). NIV was used in 151 patients with
acute respiratory failure (ARF). Patients were
divided in two groups: NIV success and NIV fail-
ure, if ETI was required. Mean age was 7.2±20.3
months (median: 1 min: 0,3 max.: 156). Main
diagnoses were bronchiolitis in 102 (67.5%),
and pneumonia in 44 (29%) patients. There was
a significant improvement in respiratory rate
(RR), heart rate (HR), pH, and pCO2 at 2, 6, 12
and 24 hours after NIV onset (P<0.05) in both
groups. Improvement in pulse oximetric satura-
tion/fraction of inspired oxygen (SpO2/FiO2)
was verified at 2, 4, 6, 12 and 24 hours after NIV
onset in the success group (P<0.001). In the
failure group, significant SpO2/FiO2 improve-
ment was only observed in the first 4 hours. NIV
failure occurred in 34 patients (22.5%). Risk
factors for NIV failure were apnea, prematurity,
pneumonia, and bacterial co-infection
(P<0.05). Independent risk factors for NIV fail-
ure were apneia (P<0.001; odds ratio 15.8; 95%
confidence interval: 3.42-71.4) and pneumonia
(P<0.001, odds ratio 31.25; 95% confidence
interval: 8.33-111.11). There were no major
complications related with NIV. In conclusion
this study demonstrates the efficacy of NIV as a
form of respiratory support for children and
infants with ARF, preventing clinical deteriora-
tion and avoiding ETI in most of the patients.
Risk factors for failure were related with imma-
turity and severe infection.
Introduction
Non-invasive ventilation (NIV) is a relative-
ly new ventilatory mode that has been increas-
ingly used in the acute setting over the past 15
years, demonstrating beneficial effects in the
adult and pediatric population with different
types of respiratory failure.1-4 NIV recruits the
lung, increasing functional residual capacity,
improves respiratory dynamics, reduces respi-
ratory work, and optimizes gas exchange.4
Several studies in the adult populations
have shown that NIV is a safe and effective
therapy for patients with hypercapnic acute
respiratory failure (ARF) due to chronic
obstructive pulmonary disease (COPD) exac-
erbation, hypoxemic ARF due to cardiogenic
pulmonary edema or community-acquired
pneumonia, and ARF in the immunocompro-
mised patients with pulmonary infiltrates.2,5 In
these patients, NIV is associated with an
improvement in respiratory status and a reduc-
tion in the length of stay in the intensive care
unit, and in mortality.2,5 It diminishes the rate
of intubation when compared to conventional
medical therapy, and the risk of ventilator
associated pneumonia and other nosocomial
infections.5,6 The overall effectiveness of NIV
in avoiding intubation ranges from 69-79% in
randomized studies.6 In adults with mixed
types of respiratory failure, including severe
hypoxemia, the evidence in support of NIV is
less strong.6,7 In hypoxemic ARF due to acute
respiratory distress syndrome (ARDS) /acute
lung injury (ALI), NIV should be applied in
carefully selected patients. When patients have
a high severity score, older age, ARDS, pneu-
monia, or fail to improve pulse oximetric satu-
ration/fraction of inspired oxygen (SpO2/FiO2)
after 1h of treatment, the risk of failure is
higher.5-7 The best-documented application of
NIV in pediatric patients is in chronic patients
in the home setting. NIV has proven to improve
or reverse nocturnal hypoventilation in infants
and children with various causes of chronic
respiratory failure, such as neuromuscular dis-
eases, severe upper airway obstruction and
cystic fibrosis.1,3,4 NIV is also a well-estab-
lished therapy in neonates for early stabiliza-
tion in very low birth weight newborns, as a
primary mode for respiratory distress syn-
drome treatment, in the management of apnea
of prematurity and for prevention of extuba-
tion failures.7 During the last 10 years NIV has
been increasingly used in children with acute
respiratory distress. Although the reported
studies on this form of ventilatory support are
mainly retrospective, non-controlled clinical
trials and little case series are being increas-
ingly published and recently prospective stud-
ies have shown that NIV appears to be a safe
and effective treatment in children with acute
respiratory problems.8-22 The success of treat-
ment with NIV was documented by clinical and
laboratory parameters such as respiratory rate
(RR) and cardiac rate (HR) and improvement
of blood gas variables.8-15
NIV is being considered by many centers as
an early alternative form of ventilatory support
for acute respiratory failure.9,15 Information on
pediatric NIV characteristics and risk factors
for NIV failure in children are useful to
improve therapeutic strategies of respiratory
support. We report our experience with the use
of NIV as a primary ventilatory support in chil-
dren admitted to our Pediatric Intensive care
Unit (PICU), with acute respiratory distress. 
The primary objective of the present study
was to assess the clinical efficacy of NIV in
avoiding endotracheal intubation and to
demonstrate clinical and gasometrical
improvement in those patients. The secondary
objective was to identify predictive risk factors
associated with NIV failure and the need for
endotracheal intubation.
Materials and Methods
The study was performed in a PICU with 5
intensive care beds and 6 special care beds.
Pediatric Reports 2012; volume 4:e16
Correspondence: Clara Abadesso, Pediatric
Intensive Care Unit, Hospital Fernando Fonseca,
IC 19, 2720-276, Amadora, Portugal.
Tel: +351917905002. 
E-mail: clara_abadesso@hotmail.com
Key words: non-invasive ventilation, acute respi-
ratory failure, child, infant, predictive factors,
pediatric intensive care unit.
Acknowledgments: we thank Dr. Michele Costa
for helping in the translation of this manuscript.
We thank our nursing staff for their involvement
in learning and performing non-invasive ventila-
tion, with great cooperation and enthusiasm.
Contributions: CA, PN, conception and design,
acquisition of data, analysis and interpretation of
data, drafting the article and revising it critically;
CS, HA, conception and design, acquisition of
data, analysis and interpretation of data, revising
the article critically; EM, HL, acquisition of data,
analysis and interpretation of data; revising the
article critically. 
Conflict of interests: all authors declare that
there are no conflicts of interest.
Received for publication: 5 February 2012.
Revision received: 
Accepted for publication: 
This work is licensed under a Creative Commons
Attribution NonCommercial 3.0 License (CC BY-
NC 3.0).
©Copyright C. Abadesso et al., 2012
Licensee PAGEPress, Italy
Pediatric Reports 2012; 4:e16
doi:10.4081/pr.2012.e16
[page 58] [Pediatric Reports 2012; 4:e16]
Intervention
NIV was used as a primary ventilatory sup-
port in patients with acute respiratory dis-
tress/failure, with the objective of clinical
improvement and avoidance of endotracheal
intubation. We used a written standardized
protocol, based on the guidelines published by
Respiratory Group of the Spanish Society of
Pediatric Intensive Care.23Design and setting
This is a cohort study with prospective data
collection regarding patients treated with NIV.
We considered two groups: a success group,
where clinical and gasometric improvement
was achieved and a failure group, where intu-
bation was necessary.Study period
From November 2006 to January 2010 (3
years and 2 months).Patients
We included patients admitted to our PICU
with need of NIV as a primary ventilation
mode. The inclusion criteria were: acute respi-
ratory failure (hypoxemia - transcutaneous
oxygen saturation (SpO2) < 92% at room air
and capillary or venous pCO2 > 50-60 mmHg),
exacerbation of chronic respiratory failure,
severe upper airway obstruction and apnea.
Clinical status of the patient and the work of
breathing were also important factors when
deciding to begin NIV. Patients were selected
regardless of the underlying disease process
contributing to respiratory failure. Exclusion
criteria were: cardiorespiratory arrest, hemo-
dynamic instability despite vasoactive treat-
ment, Glasgow coma score <8, need for airway
protection or need of immediate intubation to
avoid respiratory arrest. Patients with NIV
after extubation were not included in this
study, although we use it as a method of wean-
ing from mechanical ventilation.
Bronchiolitis was defined as a respiratory
disorder in children from 1 month to 2 years of
age, presenting with rhinitis, tachypnea,
cough, wheezing, crackles, and use of accesso-
ry muscles, with or without fever, and without
a consolidation on the x-ray.
Viral pneumonia was defined as a respirato-
ry disorder with a new or progressive infiltrate
or consolidation on a chest x-ray, and tachyp-
nea, cough, wheezing, crackles, and use of
accessory muscles, with or without fever.
Bacterial co-infection was considered in the
presence of at least two of the following: fever
>38ºC, increased C-reactive protein > 5 mg/dL,
leucocitosis> 15.000 mm3, and new or progres-
sive infiltrate (interstitial, bronchial, alveolar)
or consolidation on the chest X-ray.
These criteria were usually used to start
antibiotics.
Ventilatory support strategies
The ventilatory strategy was based on the
guidelines mentioned above.23
NIV was delivered by continuous (CPAP) or
bi-level (BiPAP) positive airway pressure. 
The interface to the patient was chosen
between the following four (according to
patient age, comfort and availability): nasal or
mouth-nose mask, binasal short prosthesis
and nasopharyngeal prosthesis (endotracheal
tube with its extremity cut and placed on the
nasopharynx). 
Conventional (Drager Babylog 8000 plus®)
and specific NIV ventilators: Respironics
BiPAP Vision®, Respironics BiPAP Harmony®,
Infant Flow Driver®, Infant Flow Advance®/
SiPAP®, were used to apply NIV.
CPAP was begun with 4-5 cmH2O, and pro-
gressively increased the pressure according to
the need/tolerance of the patient. BiPaP was
begun with an expiratory positive airway pres-
sure (EPAP) of 4-5 cmH2O and an inspiratory
positive airway pressure (IPAP) of 8-10
cmH2O. IPAP was then increased by 2 cmH2O
intervals according to the patient’s needs and
tolerance. CPAP or BIPAP was chosen depend-
ing on: if it was type I or type II acute respira-
tory failure, ventilators available or patient’s
tolerance/improvement.
The necessary inspiratory fraction of oxygen
was used to maintain a SpO2 above 94%. With
the BiPaP Harmony®, supplemental oxygen
was administered through the circuit to
achieve SpO2 > 94%. Ventilator parameters
were adjusted according to clinic and gasomet-
rical evolution. In every case a minimum respi-
ratory backup frequency was programmed,
ranging from 10 to 30 cpm depending on the
child’s age. NIV was reduced progressively in
accordance to the degree of clinical improve-
ment, and was discontinued when the patient
had normal RR for age, oxygen requirement
<40%, a lower pCO2 without ventilatory sup-
port, and periods with good clinical tolerance
without NIV support. This was a subjective
decision, non-based on any specific standard-
ized criteria.Standard treatment
Nutritional support was delivered by contin-
uous enteral feeding via naso or orogastric
tube; this was also used to avoid gastric disten-
sion. The majority of the patients received
chest physiotherapy in order to clear secre-
tions using forced expiratory technique.
Corticosteroids were never used for the treat-
ment of bronchiolitis. Prevention of skin injury
was made by the application of hidrocolloide/
colloid dressings (Askina® and Varihesive®
gel control) on different facial pressure points. 
Salbutamol nebulizer was used in patients
who respond to it. Sedation was maintained
with chloral hydrate (30-50 mg/kg) and myda-
zolam boluses (0.1 mg/kg), in order to avoid
patient-ventilator asynchrony, or in cases of
severe agitation.
Non-invasive ventilation outcomeand end-points
Patients were divided in two groups: NIV
success (Group A) and NIV failure (Group B).
NIV success was defined as: i) objective
reduction in respiratory effort, demonstrated
by reduction in RR and HR; ii) reduction in
oxygen demand; iii) improvement in gasomet-
ric parameters (ph, pCO2). NIV failure was
defined as the need for endotracheal intuba-
tion.
Intubation criteria were: absence of
improvement, worsening of gasometric param-
eters or deterioration in the clinical status of
the patient. 
We analyzed risk factors associated with NIV
failure.Data collection
Clinical data collected: RR, HR, SpO2; capil-
lary pH and pCO2 obtained before and at 2, 4, 6,
12, 24 and 48 h of NIV.
To estimate oxygenation we calculated pulse
oximetric saturation/fraction of inspired oxy-
gen (SpO2/FiO2) as a non-invasive alternative
to PaO2/FiO2.24
Some patients do not have all of the gaso-
metric evaluations in the referred time.
The following variables were also collected
for each patient: age, sex, weight, personal rel-
evant medical history (prematurity, chronic
pulmonary disease, congenital cardiac dis-
ease), ARF type, ARF cause, NIV characteris-
tics (type of mask, ventilator, NIV mode and
used parameters), use of sedatives, NIV dura-
tion, NIV outcome, NIV complications, length
of hospital stay and Pediatric Index of Mortality
score (PIM). Statistical analyses
Descriptive analysis: Results of quantitative
variables were expressed in terms of mean,
standard deviation, and median. Quantitative
related continuous variables were compared
using paired two-tailed t-test/Student T-test.
Categorical values were expressed as a per-
centage, and compared using the c2 test or the
Fisher exact test when relevant.
Univariate and multivariate analyses of risk
factors for NIV failure were performed using
logistic regression. Independent predictive fac-
tors for NIV failure were determined by multi-
variate analyses. 
A P value of <0.05 was considered statisti-
cally significant.
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ResultsPatients
During the study period 1948 children were
admitted in our Unit, 848 with respiratory dis-
ease. There were 149 children subjected to NIV
in a total of 151 NIV episodes, with each
episode treated as an independent event.
The mean age was 7.25±20.3 months (medi-
an: 1 month; range 0.3-156 months). One hun-
dred and twenty eight patients (84.7%) were
infants less than 6 month of age and 79 were
≤1 month. Mean weight was 5.1±4.9 kg and 77
(51%) were male. 
Most of the episodes occurred between
November and February of the studied years.
The most common primary diagnosis was
bronchiolitis affecting 102 patients (67.5%),
followed by pneumonia in 44 (29%). Other
diagnosis were: atelectasis in 27 (18%); apnea
in 20 (13.2%); bacterial co-infection in 43
(28.5%); upper airway obstruction in 5
(nasopharyngeal carcinoma, multiple malfor-
mation syndrome, cervical hemalynphan-
gioma, laryngomalacia); septic shock in 3;
ARDS in 3 and pericardial effusion in 1.
Patients with bronchiolitis were significant-
ly younger than those with pneumonia
(1.6±2.24 months vs. 20.2±34.3; P=0.00).
Past relevant medical history: prematurity
in 27 (18%); chronic pulmonary disease in 10
(6.6%); neurodevelopmental delay in 12; tri-
somy 21 in 5; gastroesophageal reflux in 3;
cerebral palsy in 3; oncological disease in 2;
neuromuscular disease in 1; AIDS in 1, and-
sick cell disease in 1.
The following etiologic agents were identi-
fied using antigen detection on respiratory
secretions: respiratory syncytial virus (RSV) in
85 (56.3%), adenovirus in 3 (2%), and influen-
za in 2 (1.3%). 
A bacterial agent was identified in respirato-
ry secretions or blood samples in 15 children
(5 bacterial co-infections): Haemophilus
influenzae: 5; Streptococcus pneumoniae: 2;
Streptococcus A: 2; Klebsiella pneumoniae +
Staphilococcus aureus: 1; Mycoplasma pneu-
moniae: 1; Meningococcus: 1; Bordetella per-
tussis: 1; Salmonella sp: 1.
NIV was initiated due to ARF (hipoxemic/
hypercapnic) in 144 (95.4%), apnea in 20,
exacerbation of chronic pulmonary disease in
3, and partial obstruction of the upper airway
in 5.Non-invasive ventilation character-istics
Continuous positive airway pressure
(CPAP) was used in 72 (48%) and BiPAP in 79
(52%). When using CPAP, NIV was delivered
through Drager Babylog 8000 plus® in 40
(26.5%), and Infant Flow Driver® in 31
(20.5%). When using BiPAP, Infant Flow Driver
advance/SiPAP® was used in 35 (23.2%),
Respironics BiPAP Vision® in 35 (23.2%) and
Respironics BiPAP Harmony® in 10 (6.6%).
Regarding interfaces, we used a nasopha-
ryngeal tube in 40 children, a nasal mask/nasal
prongs in 99 (65.6%), and a mouth-nose mask
in 12 (8%). 
The nasopharyngeal tubes were mainly used
with the Drager Babylog 8000 plus® when
applying CPAP during our first year, due to the
lack of NIV specific ventilators for infants.
The mean used pressures were 5.5-6 cmH2O
for EPAP/CPAP (min: 4, max: 9) and 9.5-19 cm
H2O for IPAP (min: 6; max: 24) (Table 1).Sedation
One hundred and seventeen (77.5%) chil-
dren were sedated. In 80 (53%), chloral
hydrate was used; in 35 (23%), chloral hydrate
was associated with midazolam in bolus, PRN.
Four were sedated with a low dose midazolam
(1 µg/Kg/min). In thirty-four patients no phar-
macological sedation was needed. These
patients were mainly newborns (59%). The
percentage of patients who were not sedated
was similar in both study groups (22.2 vs.
23.5%).Enteral nutrition
Fifty-one children (33.8%) remained fasted,
60 (40%) were fed by partial enteral nutrition
with a naso or orogastric tube, and in 22, total
nasogastric enteral nutrition was accom-
plished.Clinical progression and gasometri-cal evolution
Baseline values of the variables did not dif-
fer between groups.
Analysis of clinical and gasometric data
showed an overall significant decrease in RR,
HR and improvement in blood gases (pH,
pCO2) from hour 2, and maintained through
all the study (at 4, 6, 12h), until 24h after start-
ing NIV (P<0.05) (Table 2).
Although these variables decreased more in
the success group, the difference was not sta-
tistically significant between the two groups.
The improvement in SpO2/FiO2 was verified
at 2, 4, 6, 12, and 24h after initiation of NIV
only in the success group (P=0,000); in the
failure group, improvement was significant
only in the first 4 hours.
Non-invasive ventilation outcomeNon-invasive ventilation success
Of the 151 episodes, 117 (77.5%) were suc-
cessfully treated with NIV and 34 children
(22.5%) needed invasive ventilation (IV).
The criteria for intubation were: apnea with
bradicardia (10), frequent apnea (8), clinical
deterioration (4), ARDS (3), shock with car-
diac failure (1), severe hypoxemia (1), and
increased hypercapnia (7).
Baseline characteristics of successful and
failure groups are shown in Table 3.Predictive factors of non-invasiveventilation outcome/risk factorsanalysis
To identify clinical and physiological vari-
ables associated with favorable NIV outcome,
NIV success and failure groups were com-
pared.
Univariate analysis showed that pneumo-
nia, PIM, apnea, prematurity, bacterial co-
infection, and progression to ARDS were risk
factors for NIV failure (P<0.25) (Table 3).
Using multiple logistic regression including
these variables showed that the better model
(higher Hosmer and Lemeshow Test, P=0.886,
and higher area under ROC) was the one
including: apneia (P<0:001; odds ratio 15.8;
95% confidence interval: 3.42-71.4), bacterial
co-infection (P=0.067, odds ratio 2.68, 95%
confidence interval: 0.94-7.70) and pneumonia
(P<0.001, odds ratio 31.25; 95% confidence
interval: 8.33-111.11), as independent risk fac-
tors (Table 4). In this model, PIM, prematurity,
were non significant; progression for ARDS
was excluded because it only occurred in three
patients. When we constructed a multivariate
model we concluded that the relation between
factors was not an important determinant.
Patients with pneumonia who needed inva-
sive ventilation were of younger age (6.1±10
months vs. 40.6±45.7 months), the same hav-
ing occurred in patients with bronchiolitis
(0.95±0.6 vs. 1.7±2.3 months).Non-invasive ventilation adverseeffects
During the application of NIV we observed
the following complications: nasal mucosa
trauma (9), nasopharyngeal prosthesis
obstruction due to mucus hypersecretion (10),
desynchronization (5), pressure ulcers (4),
inadequate humidification (1), gastric disten-
Article
Table 1. Non-invasive ventilation parameters (n=151).
0h 1h 2h 4h 6h 12h 24h 48h
EPAP 5.5±1 5.6±1 5.7±1 5.8±1 6±1 6±1 6±1.1 6±1
IPAP 9.5±2.7 9.8±3 9.8±3 10±3 10±2.5 9.8±2.6 10±2.5 9.5±2.6
FiO2 40±1.5 40±1.3 38.5±1.2 37.7±1.1 36.3±1 36±1.3 33.4±1 33.6±7.6
There were no differences between both groups. EPAP, Expiratory positive airway pressure; IPAP Inspiratory positive airway pressure; FiO2,
Fraction of inspired oxygen
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Table 3. Comparison of group A (success) and B (failure) - clinical characteristics - univariate analysis.
Total sample NIV success group NIV failure group P value
(n=151) (n=117) (N=34)
Age
<1 month 79 61 18 0.5
<2 months 109 84 25 ns
Age (mean±sd) 7.2±20.3 7.9±22.6 4.9±9 ns
Sex (F:M) 74 : 77 55 : 62 19 : 15 ns
Weight (mean±sd) 5.1±4.9 5.3±5.4 4.4±3 ns
PIM* 3.4±7.0 (n=80) 6.9±9.0 (n=23) 0.049
Diagnosis (%)
Bronquiolitis 102 (67.5) 95 7 0.00
Pneumonia 44 (29.1) 18 26 0.00
Apnea 20 (13.2%) 9 11 0.001
Bacterial co-infection 43 (28.5%) 26 17 0.001
Septic shock 3 2 1 n.s.
Acute respiratory distress syndrome 3 0 3 0.011
Past history
Prematurity 27 (18%) 17 10 0.045
Chronic pulmonary disease 10 (6.6%) 10 0 0.07
Neurodevelopment delay 12 8 4 0.27
Duration of NIV (hours) 48.3±39 56.4±38 20.3±28 0.00
Duration of hospital stay (days) 9.7±9.5 8.4±8.8 14.5±10.2 0.003
*PIM only determined in children > 1 month and < 16 years.NIV, non-invasive ventilation; PIM, pediatric index of mortality score; ns, not significant.
Table 4. Multivariate analysis regression for risk factors.
Odds ratio 95% confidence interval for odds ratio P value
Apnea 15.8 3.42-71.4 0.000
Bacterial co-infection 2.68 0.94-7.70 0.067
Pneumonia 31.25 8.33-111.11 0.000
Table 2. Evolution of clinical and gasometric parameters. Clinical evolution for the first 24h: paired T test showed significant improve-
ment at 2. 4. 6. 12. and 24 h for all parameters in group A as well as in group B for respiratory and cardiac rate.
Group Pre-NIV 2h (n=142) 4h (n=137) 6h (n=132) 12h (n=122) 24h (n=102)
Respiratory rate (cpm) A 59±15.4 43.4±13.2 (P<0.001) 40.5±11.3 (P<0.001) 41.2±13 (P<0.001) 39±10.4 (P<0.001) 37.3±10.2 (P<0.001)
B 59.4±18.7 42.4±9.1(P=0.001) 43.6±12 (P=0.005) 42±10.6 (P=0.004) 40.3±13.2 (P<0.001) 38.5±13 (P=0.01)
Heart rate (bpm) A 164.5±19 149±19.3 (P<0.001) 147±14.5 (P<0.001) 143±18 (P<0.001) 140±15.1 (P<0.001) 138±14.5 (P<0.001)
B 164.7±17.6 151±19 (P=0.01) 149±19.4 (P=0.001) 145±18.6 (P<0.001) 143±18 (P<0.001) 141.6±13 (P=0.001)
pH A 7.29±0.07 7.35±0.06 (P<0.001) 7.35±0.05 (P<0.001) 7.35±0.05 (P<0.001) 7.37±0.05 (P<0.001) 7.39±0.05 (P<0.001)
(n=63/117) (n=66/117) (n=54/114) (n=74/106) (n=75/92)
B 7.27±0.09 7.31±0.05 (P=0.006) 7.33±0.06 (P=0.07) 7.34±0.06 (P=0.03) 7.33±0.05 (P=0.07) 7.35±0.03 (P=0.01)
(n=16/25) (n=15/20) (n=12/18) (n=11/16) (n=7/10)
Carbon dioxide partial A 62.5±12.5 58.2±11.7 (P<0.001) 54.1±7.1 (P<0.001) 56±9.6 (P<0.001) 52.5±6 (P<0.001) 51.5±6.3 (P<0.001)
pressure (n=63/117) (n=66/117) (n=54/114) (n=74/106) (n=75/92)
B 63±10.7 60.4±9.5 (P=0.03) 56.7±13.4 (P=0.048) 57±14 (P=0.01) 57±12 (P=ns) 57.7±9 (P=ns)
(n=16/25) (n=15/20) (n=12/18) (n=11/16) (n=7/10)
SpO2/FiO2 A 2.6±0.7 2.74±0.6 (P<0.001) 2.8±0.6 (p<0.001) 2.9±0.65 (P<0.001) 3.0±0.65 (P<0.001) 3.0±0.57 (P<0.001)
(n=101) (n=97) (n=96) (n=87) (n=71)
B 2.5±0.8 2.5±0.8(P<0.001) 2.6±0.66(P=0.003) 2.7±0.75(P=ns) 2.7±0.74(P=0.016) 2.67±1.0(P=ns)
(n=24) (n=20) (n=18) (n=16) (n=10)
Group A: Non-invasive ventilation (NIV) success group (n=117); Group B: NIV failure group (n=34). At 2.4.6.12 and 24h number of patients on NIV is indicated. P value: two-tailed T-test - analysis of variance of val-
ues before and after NIV (at 2. 4. 6 12 and 24h) in each group. Number of patients who had gasimetric evaluation at the considered hours is referred. Pulse oximetric saturation/fraction of inspired oxygen
(SpO2/FiO2) is not considered when SpO2 is > 96%.
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sion (1), and conjunctivitis (1). None of these
complications were responsible for NIV failure.Non-invasive ventilation duration
The mean duration of NIV was 48.3±39
hours (range 1-209 hrs). NIV duration in the
failure group was: <1h: in 4 patients; between
1 and 12h:  in 17; and > 12h: in 13. Timing and
reasons for endotracheal intubation are shown
in Figure 1.Hospital stay
The mean hospital stay was 9.7±9.5 days
(median 8). The difference between the two
groups was statistically significant (Table 3).Mortality
Two patients died; both deaths were related
with underlying disease (AIDS and end-stage
oropharynx carcinoma).
Discussion
Our results show that pediatric patients
with acute respiratory insufficiency/distress
can improve with NIV used as a primary venti-
latory support. The overall success rate was
77.5%. Clinical evidence of response was asso-
ciated with improvement in RR and HR as well
as blood gases (pH and pCO2). This improve-
ment was evident, and statistically significant,
since the first hours of NIV, and was observed
in both the success and failure group for RR
and HR. Decrease of pCO2 was not significant
in the failure group at 12 and 24h, but gasimet-
ric data is available in a small number of
patients.
The indirect measure of oxygenation using
the SatO2/FiO2 ratio also showed a significant
improvement in the success group, but was not
very consistent in the failure group.
This clinical improvement has been
described in previous studies.9-15
NIV as primary ventilatory support prevents
the clinical deterioration of some patients,
where it could lead to the need for intubation,
and ensures a better respiratory comfort,
shown by the improvement in clinical parame-
ters. Previous studies have shown success
rates for NIV in the pediatric population to be
between 57 and 92%.8-18 In the retrospective
study done by Javouhey et al.,20 a ventilatory
strategy using NIV as primary ventilatory sup-
port in severe bronchiolitis was associated
with a decreased incidence of ventilator asso-
ciated pneumonia, less oxygen support, and a
reduction in hospital stay, when compared
with a period when NIV was not used. The suc-
cess rate was of 81%.
Different success rates are probably related
to heterogeneity of the groups regarding age
and diagnosis. 
In this study, independent risk factors for
NIV failure were apnea and pneumonia. These
factors were also identified in previous stud-
ies.9-15 Other factors were also previously, con-
sidered relevant: younger age,11 higher PRISM
score,10-14 ARDS9 type I ARF,10 and failure to
decrease RR.9-10 In our study the patients were
in majority small infants, the severity score
used was PIM, pneumonia is associated with
type I ARF; the clinical and gasometric
improvement in our group didn’t seem to be
good predictive factors.
In a 5-year observational study, where 114
children with different causes of respiratory
failure (community-acquired pneumonia,
immunodeficiency, and sickle cell disease)
were included, Essouri et al.,9 illustrated an
overall success rate of 77%. Favorable outcome
was predicted by breathing pattern evolution
within the first 2 hrs of NIV (a significant
decrease in pCO2 and RR was observed in the
NIV success group). Multivariate analysis
showed that ARDS and a high PELOD score
were independent risk factors for NIV failure.9
The largest prospective study of NIV out-
come predictors in pediatric ARF, included 116
episodes of NIV.10 This study included a typical
heterogeneous, critically ill pediatric popula-
tion with a median age of 10.3 months (0.6-
169.7). The success rate was 84%. Three inde-
pendent risk factors for NIV failure were iden-
tified: type 1 ARF, high PRISM score, and lower
RR decrease during initial NIV phase.
Hypoxemic ARF patients are more likely to
suffer NIV failure, as shown by most of the pre-
vious studies in adults and children.6,9,10 In
adult patients with hypoxemic respiratory fail-
ure, pneumonia, ARDS, or failure of PaO2/FiO2
increase >146 after the first hour of NIV ther-
apy have been associated with increased risk
of NIV failure.2,5,6
In our series NIV failure occurred in 26 out
of 44 patients with pneumonia, and in only 7
out of 95 patients with bronchiolitis. Pneumo -
nia and progression to ARDS were risk factors
for NIV failure.
The fact that the SpO2/FiO2 improvement
was not consistent in the failure group is prob-
ably associated with type 1 ARF predominance
in this group. For this reason, it is extremely
important to classify patients as type 1 or 2 ARF
before starting NIV.10
PRISM score has already been illustrated as
a predictive factor for NIV outcome.10-13 In our
study PIM was higher in the failure group,
although not significant in the multiple logis-
tic regression.
Younger age, shown to be a risk factor for
NIV failure in several other studies,10,11,13 may
be related to other associated factors (e.g.
increased occurrence of apnea in the neonatal
period) or technical problems (e.g. use of inap-
propriate interfaces, use of NIV ventilators
without a specific trigger for this age group). 
Our study had a very low median age [1
month: (0.26-156)], with the main diagnosis
having been bronchiolitis (n=102; 67.5%).
Other studies that have included only infants
with bronchiolitis also had a low median
age.12,13
The use of NIV in severe bronchiolitis, and
its physiological effects in the improvement of
respiratory work (clinically evaluated by a
reduction in the RR) and blood gas exchange,
have been described since 1981.12-14,19,21
Soong et al.,21 studied 10 infants with bron-
chiolitis and impending respiratory failure in a
non-randomized study. They reported improve-
ment in clinical signs and symptoms, and
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Figure 1. Timing and reasons for endotracheal intubation. (n=34). Non-invasive ventila-
tion failure ≤ 12 h = 21; 12-24 h = 5; > 24 h = 8; ARDS, Acute respiratory distress syn-
drome. 
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physiologic parameters (HR, RR, PaCO2, and
oxygenation index) after two hours of CPAP.
S. Larrar et al.,12 illustrated significant
improvement in respiratory status shown by
decrease in RR and HR, in a prospective study
with 53 infants with bronchiolitis. The success
rate was 75.5%. Predictive factors associated
with NIV failure were a higher PRISM score
and a smaller initial reduction in the PaCO2
(between the 12th and 16th hour). This PaCO2
decrease was significantly higher in the suc-
cess group (P=0.003). In the failure group,
PRISM score was significantly higher when
compared to the success group (9.2±4.1 vs.
5.1±3.2, P=0.002).12
In a series of 69 infants with bronchiolitis,
Campion et al.,13 had a NIV success rate of
83%. They presented a significant decrease in
pCO2, and an increase in pH at 2 and 4 hours
after beginning NIV. Factors associated with
NIV failure were pCO2 at admission (80 vs. 66),
higher PRISM score (15 vs. 10), and apnea.
In an analysis of 47 patients with bronchioli-
tis treated with NIV, Mayordomo-Colunga et
al.11, identified apnea (23.1% vs. 75%;
P=0.004), background medical history (84.6%
vs. 50%; P=0.029) and smaller reduction in the
HR at 1 and 12 hours after beginning  NIV, as
risk factors for NIV failure. A reduction in the
HR by 11 bpm or higher predicted NIV success
with 64.1% sensibility and 87.5% specificity.
They also observed that patients in the failure
group presented a lower RR before initiating
NIV, and a smaller reduction in this parameter
in the following hours. Other parameters with
statistical relevance between the two groups
were weight and age.
Thia et al.,14 conducted a randomized con-
trolled trial (n=31) comparing nasal CPAP and
standard treatment in children with bronchi-
olitis. There was a significantly greater change
in pCO2 following CPAP given as first line ther-
apy when compared to CPAP given as second
option. No significant differences were seen in
HR or RR. The difference seen between early
and late use of NIV is probably related to the
fact that early treatment prevents the develop-
ment of additional airway collapse and further
tiring. Therefore, it appears that early use of
NIV slows and reverses the natural progression
of the disease, supporting its early use in clin-
ical practice.14
Another prospective study, conducted by
Bernet et al.,15 included 42 children with a
median age 2.45 years (range, 0.01-18 yrs).
The success rate was 57% having been com-
posed by a very heterogeneous group of
patients (bronchiolitis, pneumonia, postopera-
tive congenital cardiopathy, hyaline membrane
disease, etc). There was a significant improve-
ment of respiratory variables (pH, pCO2, RR
and HR) during the first 8 hours in both
groups. During the first hour, a decrease in RR
was documented only in the success group.
FiO2 after 1 hour of NIV was significantly
lower in responders when compared to non-
responders (P<0.02). An FiO2 >0.8 at 1 hour of
NIV predicted failure with a sensitivity of 56%,
specificity 83%, positive predictive value of
71%, and negative predictive value of 71%.
FiO2 at 1hour was not different between
patients with and without successful NIV>
24hrs (P=0.58).
Other studies have identified the occur-
rence of apnea as a predictive factor of NIV
failure.11,13,19
Predictors of NIV success or failure are help-
ful in selecting patients. Most studies show
that the best predictor of NIV success is a
favorable response to NIV within the first
hours (reduction in RR, improvement in pH,
improvement in oxygenation, reduction in
PaCO2.10-19 This emphasizes the importance of
the close monitoring in these patients. If a
reduction in RR or HR fails to occur, close sur-
veillance must be undertaken and ETI should
be considered.
Complications were minimal, therefore not
interfering with the application or efficacy of
NIV. There were no documented cases of baro-
trauma or aspiration. The occurrence of gas-
tric distension was non-significant (1 case
only), and this was probably related to the use
of a nasogastric tube for enteral feeding.
Although agitation during initial mask place-
ment was observed in several infants, no
patient required NIV discontinuation due to
poor tolerance. Skin lesions occurred more fre-
quently during the early phase of NIV use in
our Unit. Incidence decreased with the routine
use of protective patches over pressure points,
prior to mask application. The potential inca-
pacity of young children to trigger the inspira-
tory pressure support is one of the limitations
of NIV use in small children. A second techni-
cal challenge pertains to the correct mask
interface selection. Important issues to consid-
er when selecting an interface are patient
comfort and optimum fit to minimize leakage.
In some patients, the use of sedation is an
important adjuvant to the success of NIV, and
may help overcome synchronization problems.
This study shows the relevance of the use of
NIV guidelines leading to a greater utilization
of NIV and, by taking risk factors for NIV fail-
ure into account, to better clinical judgment.
Once begun, patients should be closely moni-
tored; attention should be paid to vital signs,
gas exchange, comfort, and tolerance. 
The use of NIV in children does not mean
that less monitoring and/or care is needed,
when compared to invasive forms of mechani-
cal ventilation. In fact, after initiation of NIV
for acute respiratory distress, close bedside
assessment of efficacy is essential. Children
treated with NIV must be observed by qualified
professionals, guided by the use of cardio-res-
piratory monitoring, pulse oximetry, and blood
gases when necessary. Limitations of our study
are related to the lack of randomization, lack of
standardized weaning protocols for infants
treated with NIV, and probably to the use of
subjective criteria for initiating invasive venti-
lation in some patients. Although randomized
controlled studies regarding the use of NIV in
children are needed,25 this may post an ethical
problem since scientific evidence defending
the use of NIV already exists. Published retro-
spective and prospective studies show that NIV
is in fact an effective alternative ventilatory
support method that should be applied early in
the course of respiratory distress, in order to
avoid clinical deterioration and prevent ETI in
some patients.
Factors essential to NIV success include the
careful selection of patients, a properly timed
intervention, a comfortable and well-fitting
interface, coaching and encouragement of
patients, careful monitoring, and a skilled and
motivated team.6 Indeed, the efficacy of NIV
also seems to be closely linked to the experi-
ence and motivation of the care team.9
Patients that may benefit from the use of
NIV are being more clearly defined. When tak-
ing into account the fact that early initiation of
NIV seems to be the major factor affecting NIV
success, defining specific criteria for NIV
implementation is difficult.
The elaboration of prospective, multi-cen-
tered studies is still necessary, in order to con-
tinue identifying possible predictors of NIV
success or failure.
Conclusions
When instituted at an early phase of ARF,
NIV can be effective in improving or reversing
acute respiratory distress in selected patients,
and can decrease the need for endotracheal
intubation. The increased use of NIV in our
PICU during the past years clearly reflects the
interest, motivation and experience of the
entire PICU staff. 
This study brings additional data to litera-
ture on NIV used on acute respiratory setting
in children, focusing on the efficacy of NIV, and
trying to identify possible predictors of failure
or success.
As suggested by some other authors9 we pro-
pose this ventilatory support as a first line
treatment in children with acute respiratory
distress. However children with hypoxemic
ARF should start NIV with special attention, as
evolution to ARDS is highly associated with
failure in this group.
It is possible that with increasing experi-
ence, guidelines for NIV pediatric use may be
appropriately refined improving NIV outcome
in children. With technical advances and new
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evidence of its proper application, this tech-
nique is likely to expand.
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